Thermo Fisher Scientific's MyeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing To Quickly Match Patients With Appropriate Trials Across North America
Thermo Fisher Scientific's MyeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing To Quickly Match Patients With Appropriate Trials Across North America
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America
myeloMATCH精准医学临床试验利用次日基因组测序技术快速将患者与适当的试验匹配在北美范围内
To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients' bone marrow and blood for certain genetic biomarkers using Thermo Fisher's next-generation sequencing (NGS) technology, clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.
为了加速急性髓性白血病（AML）和骨髓增生异常综合症（MDS）新治疗方法的研究，全球科学服务领导者Thermo Fisher Scientific（纽交所：TMO）正在与NCI（美国国家卫生研究院的组成部门）合作，开展myeloMATCH（分子分析用于治疗选择）精准医学伞形试验。通过利用Thermo Fisher的下一代测序（NGS）技术测试患者的骨髓和血液中的某些基因生物标志物，临床医生可以更快地将患者与测试针对样本中存在的特定突变的治疗方案的适当临床试验相匹配。